Hepatotoxicity due to commonly-used drugs;Hepatotoxicidad secundaria a fármacos de uso común

Gastroenterologia y Hepatologia

Volumn 28, Issue 8, 2005, Pages 461-472

  Garcia Cortes M ^a   Andrade, R J ^a,b   Lucena, M I ^a   Gonzalez Grande R ^a   Camargo, R ^a   Fernandez Bonilla E ^a   Martos, J V ^a   Alcantara R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b Facultad de Medicina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACEDAPSONE; ALLOPURINOL; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; BENTAZEPAM; CALCIUM ANTAGONIST; CHLORPROMAZINE; CONTRACEPTIVE AGENT; CORTICOSTEROID; DICLOFENAC; DILTIAZEM; DIPHENHYDRAMINE; ESTROGEN; HALOTHANE; ISONIAZID; MACROLIDE; METHOTREXATE; METHYLDOPA; NEFAZODONE; NICOTINIC ACID; PARACETAMOL; PHENYTOIN; SULFADIMIDINE; TAMOXIFEN; TETRACYCLINE DERIVATIVE; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID;

ADENOCARCINOMA; BUDD CHIARI SYNDROME; CHOLANGITIS; FATTY LIVER; GRANULOMATOUS HEPATITIS; HEPATITIS; HUMAN; LIVER ADENOMA; LIVER FIBROSIS; LIVER TOXICITY; REVIEW;

EID: 27444440029     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079002     Document Type: Article

References (69)

1. e mise á jour du fichier bibliographique des atteintes hépatiques et des médicaments reponsables. Gastroenterol Clin Biol. 2000;24:1052-91.
2. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002; 22:145-55.
3. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-54.
4. Bakke OM, Manocchia M, De Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58:108-17.
5. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003; 349:474-85.
6. Andrade RJ, Lucena MI, on behalf of the Spanish Group for the study of Drug-Induced liver disease. Analysis of 400 cases of hepatotoxicity submitted to a registry in Spain (1994-2003). [abstract]. Rev Clin Esp. 2004;204 Suppl:12.
7. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004;39:1430-40.
8. Bonkovsky HL, Kane RE, Jones DP, Galinsky RE, Banner B. Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology. 1994;19:1141-8.
9. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 1995; 17:1118-27.
10. Andrade RJ, Camargo R, Lucena MI, González-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf. 2004;3:329-44.
11. García Rodríguez LA, Williams R, Derby LE, Jick SS. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994;154: 311-6.
12. Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis. 2003;7:401-13.
13. O'Connor N, Dargan PI, Jones AL. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM. 2003;96: 787-91.
14. Fontana RJ, McCashland TM, Benner KG, Appelman HD, Gunartanam NT, Wisecarver JL, et al. Acute liver failure associated with prolongued use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg. 1999;5:480-4.
15. Tolman KG. Hepatotoxicity of non-narcotic analgesics. Am J Med. 1998;105:13S-9S.
16. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol. 2003;192: 307-22.
17. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology. 1995;22:820-7.
18. Tarazi EM, Harter JG, Zimmerman HJ, Ishak KG, Eaton RA. Sulindac associated hepatic injury analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology. 1993; 104:569-74.
19. Sternlieb P, Robinson RM. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. N Y Stat J Med. 1978;78:1239-43.
20. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, anti-diabetic agents, anticonvulsants, lipid lowering agents, psychotropic drugs. Semin Liver Dis. 2002;22:169-83.
21. Andrade RJ, Lucena MI, García-Cortés M, García-Ruiz E, Fernández-Bonilla E, Vázquez L. Chronic hepatitis C, ibuprofen, and liver damage. Am J Gastroenterol. 2002;97:1854-5.
22. Zimmerman HJ. Effects of aspirin and acetaminophen on the liver. Arch Intern Med. 1981;141:333.
23. Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf. 2002;25:633-48.
24. Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety of and the tolerability of the novel cyclooxigenase-2 inhibitor celecoxib. Am J Ther. 2000;7:153-8.
25. Galan MV, Gordon SC, Silverman AL. Celecoxib-induced cholestatic hepatitis. Ann Intern Med. 2001;134:254.
26. Huster D, Schubert C, Berr F, Mossner J, Caca K. Rofecoxib-induced cholestatic hepatitis: treatment with molecular absorbent recycling system (MARS). J Hepatol. 2002;37:413-4.
27. Papachristou GI, Demetris AJ, Rabinovitz M. Acute cholestatic hepatitis associated with long-term use of Rofecoxib. Dig Dis Sci. 2004;49:459-61.
28. Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology. 2002;35:876-82.
29. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet. 1995;346:547-52.
30. Zimmmerman HJ. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. Philadelphia: Lippincott Williams & Wilkins; 1999.
31. George DK, Crawford DHG. Antibacterial-induced hepatotoxicity. Incidence, prevention and management. Drug Saf. 1996; 15:79-85.
32. Friis H, Andreasen PB. Drug-induced hepatic injury: analysis of 1100 cases reported to The Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med. 1992; 232:133-8.
33. Lucena MI, Camargo R, Andrade RJ, Pérez-Sánchez CJ, Sánchez de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123-30.
34. García-Rodríguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 1996;156:1327-32.
35. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992;15:154-61.
36. Meyers BR. Comparative toxicities of third-generation cephalosporins. Am J Med. 1985;79:103.
37. Schiffman ML, Keith FB, Moore EW. Patoghenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. 1990;99: 1772-8.
38. Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, et al. Acute liver disease associated with erythromycins, sulfonamides and tetracyclines. Ann Int Med. 1993;119:576-83.
39. Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibacterials. Drug Saf. 1993;9:346-64.
40. Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology. 1994;107: 1844-7.
41. Lucena MI, Andrade RJ, Rodrigo L, Salmerón J, Álvarez A, López-Garrido MJ, et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis. 2000;30:400-1.
42. García-Rodríguez LA, Duque A, Castellsague J, Pérez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal agents. Br J Clin Pharmacol. 1999;48:847-52.
43. Derby L, Gutthann SP, Jick H, Dean AD. Liver disorders in patients receiving chlorpromazine or isoniazid. Pharmacotherapy. 1993;13:353-8.
44. Brown SJ, Desmond PV. Hepatotoxicity of antimicrobial agents. Semin Liver Dis. 2002;22:157-67.
45. Andrade RJ, Lucena MI, Vega JL, Torres M, Salmeron FJ, Bellot V, et al. Acarbose-associated hepatotoxicity. Diabetes Care. 1998;21:2029-30.
46. Schneider HL, Hornbach KD, Kniaz JL, Ecfrusy ME. Chlorpropamide hepatotoxicity: report of a case and review of the literature. Am J Gastroenterol. 1984;79:721-4.
47. Deutsch M, Kountouras D, Dourakis SP. Metformin hepatotoxicity. Ann Intern Med. 2004;140:408-9.
48. Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf. 2001;10:537-47.
49. Marcy TR, Britton ML, Blevins SM. Second generation thiazolidindiones and hepatotoxicity. Ann Pharmacother. 2004;38: 1419-23.
50. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003;7:415-33.
51. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287-92.
52. Hodis H. Acute hepatic failure associated with the use of low-dose sustained-release niacin. JAMA. 1990;264:181.
53. Stumpf JL. Fatal hepatotoxicity induced by hidralazine or labetalol. Pharmacotherapy. 1991;11:415-8.
54. Farell GC. Drugs and steatohepatitis. Semin Liver Dis. 2002; 22:185-94.
55. Clark J, Zimmerman HJ, Tanner L. Labetalol hepatotoxicity. Ann Intern Med. 1990;113:210-3.
56. Hagley MT, Hulisz DT, Burns CM. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. Ann Pharmacother. 1993;27:228-31.
57. Andrade RJ, Lucena MI, Fernández MC, Vega JL, García- Cortés M, Casado M, et al. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. Eur J Gastroenterol Hepatol. 2002;14:887-90.
58. Chang CC, Petrelli M, Tomashefski JF, McCullough AJ. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med. 1999;123:251-6.
59. Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology. 1997;112:1707-9.
60. Andrade RJ, Lucena MI, Aguilar J, Lazo MD, Camargo R, Moreno P, et al. Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. Dig Dis Sci. 2000;45:1400-4.
61. Davis M. Hepatotoxicity of antidepressants. Int Clin Psychopharmacol. 1991;6:97-103.
62. Capella D, Bruguera M, Figueras A, Laporte JR. Fluoxetine-induced hepatitis: why is postmarketing surveillance needed? Eur J Clin Pharmacol. 1999;55:545-6.
63. Lucena MI, Andrade RJ, Gómez-Outes A, Rubio M, Cabello MR. Acute liver failure after treatment with Nefazodone. Dig Dis Sci. 1999;44:2577-9.
64. Smythe MA, Umstead GS. Phenytoin hepatotoxicity: a review of the literature. DICP. 1989;23:13-8.
65. Romero-Falcón A, De la Santa-Belda E, García-Contreras R, Varela JM. A case of valproate-associated hepatotoxicity treated with L-carnitine. Eur J Intern Med. 2003;14: 338-40.
66. Martínez P, González de Etxabarri S, Ereño C, López G, Hinojal C, Teira R. Insuficiencia hepática, aduga, grave por carbamazepina. Rev Esp Enferm Dig. 1993;84:124-6.
67. Kapetanovic IM, Torchin CD, Strong JM, Yonekawa WD, Lu C, Li AP, et al. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem Biol Interact. 2002;142:119-34.
68. Overstreet K, Costanza C, Behling C, Hassanin T, Masliah E. Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review. Dig Dis Sci. 2002;47:1921-5.
69. Doan RJ, Clendenning M. Topiramate and hepatotoxicity. Can J Psychiatry. 2000;45:937-8.